INJ. 5 - FLU 500 MG

INJ. 5 - FLU 500 MG
Product Description

USE IN - PALLIATIVE MANAGEMENT OF CARCINOMA OF THE COLON , RECTUM , BREAST , STOMACH AND PANCREAS.

RMPL Pharma LLP

  • IN
  • 2018
    On CPHI since
  • 1 - 24
    Employees
Company types
Pharmaceutical company
Wholesale/Retail
Specifications

RMPL Pharma LLP

  • IN
  • 2018
    On CPHI since
  • 1 - 24
    Employees
Company types
Pharmaceutical company
Wholesale/Retail

More Products from RMPL Pharma LLP (99)

  • Ves-ATRA Softgel

    Product Ves-ATRA Softgel

    Tretinoin Soft Gelatin Capsules.
  • INJ. MELKERAN 50 MG

    Product INJ. MELKERAN 50 MG

    - PALLIATIVE TREATMENT OF MULIPLE MYELOMA.- PALLIATION OF NON - RESECTABLE EPITHELIAL CARCINOMA OF THE OVARY .
  • TAB. MELKERAN 2 MG

    Product TAB. MELKERAN 2 MG

    - PALLIATIVE TREATMENT OF MULIPLE MYELOMA.- PALLIATION OF NON - RESECTABLE EPITHELIAL CARCINOMA OF THE OVARY .
  • INJ.LEUCOVORIN  CALCIUM 50 MG

    Product INJ.LEUCOVORIN CALCIUM 50 MG

    - AN ACTIVE METABOLITE OF FOLIC ACID  ( ALSO CALLED  FOLINIC ACID AND CICTROVORUM FACTOR ), WHICH DOSE NOT REQUIRE METABOLISM BY DIHYDROFOLATE REDUCTASE , THE MOLECULAR TARGET OF FOLATE ANTAGONIST- TYPE CHEMOTHERAPEUTIC DRUGS.
  • INJ. HOLOFOS 2 MG

    Product INJ. HOLOFOS 2 MG

    - INDICATED FOR USE IN COMBINATION WITH CERTAIN OTHER APPROVED ANTI NEOPLASTIC AGENT FOR THIRD - LINE CHEMOTHERAPY OF GERMS CELL TESTICULAR CANCER.- IFOSFAMIDE IS COMBINED IS COMBINED WITH MESNA FOR PROPHYLAXIS OF HEMORRHAGIC CYSTITIS.
  • INJ. HOLOFOS 1 GM

    Product INJ. HOLOFOS 1 GM

    - INDICATED FOR USE IN COMBINATION WITH CERTAIN OTHER APPROVED ANTI NEOPLASTIC AGENT FOR THIRD - LINE CHEMOTHERAPY OF GERMS CELL TESTICULAR CANCER.- IFOSFAMIDE IS COMBINED IS COMBINED WITH MESNA FOR PROPHYLAXIS OF HEMORRHAGIC CYSTITIS.
  • INJ. 5 - FLU 250 MG

    Product INJ. 5 - FLU 250 MG

    USE IN - PALLIATIVE MANAGEMENT OF CARCINOMA OF THE COLON , RECTUM , BREAST , STOMACH AND PANCREAS.
  • TAB. ARIMIZOLE 1 MG

    Product TAB. ARIMIZOLE 1 MG

     - ANASTRAZOLE  IS USE FOR ADJUTANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER.- FOR THE FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER.
    - FOR THE TRE...
  • INJ. ELOPLAT 100 MG

    Product INJ. ELOPLAT 100 MG

    - ADJUVANT TREATMENT OF STAGE III COLON CANCER  IN PATIENTS WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOUR.- TREATMENT OF - ADVANCED COLORECTAL CANCER.
  • INJ. ELOPLAT 50 MG

    Product INJ. ELOPLAT 50 MG

    - ADJUVANT TREATMENT OF STAGE III COLON CANCER  IN PATIENTS WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOUR.- TREATMENT OF ADVANCED COLORECTAL CANCER.
  • INJ. DRONIZOL 4 MG

    Product INJ. DRONIZOL 4 MG

    USE IN -- HYPERCALCEMIA OF MALIGNANCY
    - BONE METASTASES OF SOLID TUMOURS.
  • INJ. DETIZENE 200 MG

    Product INJ. DETIZENE 200 MG

    USE IN -- IN THE TREATMENT OF METASTATIC MALIGNANT MELANOMA
    - IN HODGKIN'S DESEASE AS A SECONDARY -LINE THERAPY WHEN USED IN COMBINATION WITH OTHER EFFECTIVE AGENTS.

RMPL Pharma LLP resources (1)

  • Brochure RMPL PHARMA LLP.

    The primary goal of RMPL PHARMA LLP. is to supply our consumers with pharmaceutical products by providing assurance regarding their performance safety, value and consistency. The commitment to quality is well rooted in corporate values of our company and is very essential to our continuous development & success.